endostatin + paclitaxel + cisplatin

This is a **combination therapy** consisting of three drugs: **endostatin** (usually delivered as recombinant human endostatin, also called endostar), **paclitaxel**, and **cisplatin**. - **Endostatin** is an endogenous inhibitor of angiogenesis that acts primarily by blocking the vascular endothelial growth factor (VEGF)-mediated signaling pathway. This inhibits the proliferation and survival of endothelial cells, resulting in reduced tumor angiogenesis and increased apoptosis of endothelial cells. - **Paclitaxel** is a microtubule-stabilizing chemotherapeutic agent that prevents microtubule depolymerization, causing cell cycle arrest and apoptosis in rapidly dividing tumor cells. - **Cisplatin** is a platinum-based chemotherapy that induces DNA crosslinking, inhibiting DNA synthesis and function, leading to apoptosis in cancer cells. The combination is primarily investigated as an anti-tumor regimen in solid tumors, particularly **breast cancer**, **head and neck carcinoma**, and other cancers, with the aim of harnessing both antiangiogenic and cytotoxic mechanisms for synergistic tumor inhibition[1][2][4][7]. Endostar is the trade name for recombinant human endostatin (rh-endostatin) as developed in China.

Other names

endostar + paclitaxel + cisplatinrh-endostatin + paclitaxel + cisplatinrhES + paclitaxel + cisplatinrecombinant human endostatin + paclitaxel + cisplatin